Literature DB >> 17873349

Mammary stem cells and breast cancer--role of Notch signalling.

Gillian Farnie1, Robert B Clarke.   

Abstract

Adult stem cells are found in numerous tissues of the body and play a role in tissue development, replacement and repair. Evidence shows that breast stem cells are multipotent and can self renew, which are key characteristics of stem cells, and a single cell enriched with cell surface markers has the ability to grow a fully functional mammary gland in vivo. Many groups have extrapolated the cancer stem cell hypothesis from the haematopoietic system to solid cancers, where using in vitro culture techniques and in vivo transplant models have established evidence of cancer stem cells in colon, pancreas, prostate, brain and breast cancers. In the report we describe the evidence for breast cancer stem cells; studies consistently show that stem cell like and breast cancer initiating populations can be enriched using cell surface makers CD44+/CD24- and have upregulated genes which include Notch. Notch signalling has been highlighted as a pathway involved in the development of the breast and is frequently dysregulated in invasive breast cancer. We have investigated the role of Notch in a pre-invasive breast lesion, ductal carcinoma in situ (DCIS), and have found that aberrant activation of Notch signalling is an early event in breast cancer. High expression of Notch 1 intracellular domain (NICD) in DCIS also predicted a reduced time to recurrence 5 years after surgery. Using a non-adherent sphere culture technique we have grown DCIS mammospheres from primary DCIS tissue, where self-renewal capacity, measured by the number of mammosphere initiating cells, were increased from normal breast tissue. A gamma-secretase inhibitor, DAPT, which inhibits all four Notch receptors and a Notch 4 neutralising antibody were shown to reduce DCIS mammosphere formation, indicating that Notch signalling and other stem cell self-renewal pathways may represent novel therapeutic targets to prevent recurrence of pre-invasive and invasive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873349     DOI: 10.1007/s12015-007-0023-5

Source DB:  PubMed          Journal:  Stem Cell Rev        ISSN: 1550-8943            Impact factor:   5.739


  58 in total

1.  Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species.

Authors:  M A Goodell; M Rosenzweig; H Kim; D F Marks; M DeMaria; G Paradis; S A Grupp; C A Sieff; R C Mulligan; R P Johnson
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

2.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 3.  Cancer stem cells: lessons from leukemia.

Authors:  Jean C Y Wang; John E Dick
Journal:  Trends Cell Biol       Date:  2005-09       Impact factor: 20.808

4.  p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.

Authors:  Pasquale Sansone; Gianluca Storci; Catia Giovannini; Silvia Pandolfi; Simona Pianetti; Mario Taffurelli; Donatella Santini; Claudio Ceccarelli; Pasquale Chieco; Massimiliano Bonafé
Journal:  Stem Cells       Date:  2006-12-07       Impact factor: 6.277

5.  X-inactivation patch size in human female tissue confounds the assessment of tumor clonality.

Authors:  Marco Novelli; Antonio Cossu; Dahmane Oukrif; Alberto Quaglia; Sunil Lakhani; Richard Poulsom; Peter Sasieni; Piera Carta; Marcella Contini; Anna Pasca; Giuseppe Palmieri; Walter Bodmer; Francesco Tanda; Nick Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-27       Impact factor: 11.205

6.  Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development.

Authors:  G H Smith; D Gallahan; F Diella; C Jhappan; G Merlino; R Callahan
Journal:  Cell Growth Differ       Date:  1995-05

7.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

8.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Kyle W Jackson; Erin McNicholas; Mari J Kawamura; Wissam M Abdallah; Max S Wicha
Journal:  Breast Cancer Res       Date:  2004-08-16       Impact factor: 6.466

10.  Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.

Authors:  Gillian Farnie; Robert B Clarke; Katherine Spence; Natasha Pinnock; Keith Brennan; Neil G Anderson; Nigel J Bundred
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

View more
  148 in total

Review 1.  The difficulty of targeting cancer stem cell niches.

Authors:  Mark A LaBarge
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 2.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

3.  Radiation-induced Notch signaling in breast cancer stem cells.

Authors:  Chann Lagadec; Erina Vlashi; Yazeed Alhiyari; Tiffany M Phillips; Milana Bochkur Dratver; Frank Pajonk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-27       Impact factor: 7.038

4.  Progression of Ductal Carcinoma in Situ from the Pathological Perspective.

Authors:  Pedro Oscar R Cunha; Mark Ornstein; J Louise Jones
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

5.  Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells.

Authors:  Mingyao Ying; Yingying Sang; Yunqing Li; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa; Angelo L Vescovi; Charles G Eberhart; Shuli Xia; John Laterra
Journal:  Stem Cells       Date:  2011-01       Impact factor: 6.277

6.  Alterations of the Notch pathway in lung cancer.

Authors:  Britta Westhoff; Ivan N Colaluca; Giovanni D'Ario; Maddalena Donzelli; Daniela Tosoni; Sara Volorio; Giuseppe Pelosi; Lorenzo Spaggiari; Giovanni Mazzarol; Giuseppe Viale; Salvatore Pece; Pier Paolo Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 7.  Mouse modifier genes in mammary tumorigenesis and metastasis.

Authors:  Scott F Winter; Kent W Hunter
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-26       Impact factor: 2.673

8.  Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.

Authors:  J Tammam; C Ware; C Efferson; J O'Neil; S Rao; X Qu; J Gorenstein; M Angagaw; H Kim; C Kenific; K Kunii; K J Leach; G Nikov; J Zhao; X Dai; J Hardwick; M Scott; C Winter; L Bristow; C Elbi; J F Reilly; T Look; G Draetta; Lht Van der Ploeg; N E Kohl; P R Strack; P K Majumder
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 9.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

Review 10.  Mammary gland development.

Authors:  Hector Macias; Lindsay Hinck
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jul-Aug       Impact factor: 5.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.